Atrial Fibrillation (AFib)

News

Atrial fibrillation (AFib) is the most common sustained arrhythmia that results in heart palpitations, irregular and increased heartbeat often significantly above 100 bpm. Further symptoms include tiredness, breathlessness, feeling lightheaded and chest pain.

During AFib, the two upper chambers of the heart (the atria) beat chaotically and out of coordination with the two lower chambers (the ventricles) of the heart. Atrial fibrillation with rapid ventricular rate (AFib-RVR) often requires treatment in an emergency room setting with drugs to control the heart rhythm (e.g., beta blockers or calcium channel blockers) or anti-arrhythmic drugs (e.g., flecainide or amiodarone).

An estimated 10 million people are living with AFib in China. However, because AFib can be asymptomatic, many are diagnosed only when they present with a serious cardiovascular event at the hospital. AFib can lead to blood clots, stroke, heart failure and other heart-related complications and poses significant impact to patient’s quality of life as well as China’s healthcare system.

Our partner, Milestone Pharmaceuticals, initiated a Phase 2 clinical trial in early 2021 to evaluate the safety and efficacy of etripamil nasal spray in patients with AFib. Based on this study, JIXING is currently evaluating a development & commercialization plan for China.

For further information about our partner, Milestone Pharmaceuticals, please visit https://milestonepharma.com/

Scroll to Top